Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge has advised Annehem Fastigheter on the acquisition of a property
Mandate

Vinge has advised Annehem Fastigheter on the acquisition of a property

December 19, 2023 M&A

Vinge has advised Annehem Fastigheter AB (publ) in connection with the acquisition of the property The Corner, a new-build office property in Malmö. The property value amounts to SEK 420 million.

Annehem Fastigheter is a growth-driven property company specializing in commercial, community service and residential properties in the Nordic growth regions of Stockholm, Skåne, Gothenburg, Helsinki and Oslo. The property portfolio in Annehem Fastigheter consists of 26 investment properties with a value of SEK 4,237.8 million and a lettable area of 198 thousand sqm as of 30 September 2023. The Company is listed on Nasdaq Stockholm since December 2020 and have a Nasdaq Green Designation since May 2022.

Vinge’s team consisted of Rikard Lindahl, Victor Ericsson, Kristoffer Larson, Joel Magnusson, Madelene Andersson, Michaela Ådén, Erik Kochbati and Lovisa Jonassen.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025